Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 1.00 |
| ▸ | MAPK7 | Q13164 | 14/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 13/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 4/20 | 1.00 |
| ▸ | BRD4 | O60885 | 3/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 2/20 | 1.00 |
| ▸ | DCLK2 | Q8N568 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 0.72 |
| ▸ | TTK | P33981 | 1/20 | 0.67 |
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.67 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356878 | 1.00 | LRRK2 (1.00) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL29372331 | 1.00 | LRRK2 (1.00) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| Trifluoroacetic Acid SCHEMBL30842197 | 0.94 | LRRK2 (0.89) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL17721077 | 0.93 | LRRK2 (0.87) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL618577 | 0.93 | LRRK2 (1.00) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL24307410 | 0.92 | LRRK2 (0.84) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL29582720 | 0.91 | LRRK2 (0.83) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL24334887 | 0.91 | LRRK2 (0.83) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL24334136 | 0.91 | LRRK2 (0.83) | LRRK2MAPK7DCLK1TNK2BRD4 | |
| SCHEMBL617027 | 0.91 | LRRK2 (1.00) | LRRK2MAPK7DCLK1TNK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| US-20250270507-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE OF THE ROYAL CHILDREN'S HOSPITAL (AU) | 2025-08-28 | — | — | US | disclosed |
| US-20240408145-A1 | Gene Therapy | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-12-12 | — | — | US | disclosed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | disclosed |
| US-20230159894-A1 | GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-25 | — | — | US | disclosed |
| US-20220031710-A1 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-03 | — | — | US | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10793571-B2 | Uses of diazepane derivatives | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10787640-B2 | Producing mesodermal cell types and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-29 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2015196072-A2 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015117087-A1 | USES OF DIAZEPANE DERIVATIVES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015117083-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | LRRK2 364/4885MAPK7 263/4885DCLK1 480/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | LRRK2 340/4885MAPK7 253/4885DCLK1 453/4885 |
| US-20240408145-A1 | Gene Therapy | MCL1, DNASE1L3, CDKN1A | LRRK2 2330/4885MAPK7 3690/4885DCLK1 928/4885 |
| US-20220031710-A1 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | DOT1L, IQGAP1, EZH2 | LRRK2 849/4885MAPK7 133/4885DCLK1 653/4885 |
| US-10793571-B2 | Uses of diazepane derivatives | BRDT, BRD4, BRD3 | LRRK2 1196/4885MAPK7 1861/4885DCLK1 3728/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885MAPK7 688/4885DCLK1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.